

Contents

Preface

xiii

1	Personalized Medicine for Cancer: Introduction and Overview of the Book	1
	<i>Il-Jin Kim and David Jablons</i>	
1.1	Changing the Treatment Paradigm for Cancer	1
1.2	Companion Diagnostics and New Sequencing Technologies	3
1.3	Early Detection of Cancer and Tumor Recurrence Monitoring: Circulating Tumor Cell (CTC) and Circulating Tumor DNA (ctDNA)	5
1.4	Cancer Animal (Mouse) Models and Microenvironment for Personalized Medicine	6
1.5	Personalized Immunotherapy	7
1.6	Hereditary Cancer Syndromes and Potential Treatment	7
1.7	Future Directions	8
2	Personalized Medicine in Lung Cancer	15
	<i>Daniela Morales-Espinosa, Silvia García-Román, and Rafael Rosell</i>	
2.1	Introduction	15
2.1.1	Predictive Models	16
2.1.2	The Molecular Diagnostics Approach	17
2.1.3	Conventional Chemotherapy	19
2.1.3.1	Cisplatin	19
2.1.3.2	Pemetrexed	20

2.1.3.3	Gemcitabine	21
2.1.3.4	Taxanes	22
2.2	Genetic Alterations and New Potential Targets	23
2.2.1	Receptor Tyrosine Kinases	24
2.2.1.1	EGFR inhibitors (first and second generation)	24
2.2.1.2	ALK rearrangement (first and second generation)	25
2.2.1.3	ROS1	26
2.2.2	Epigenetic Factors	27
2.2.3	Transcription Factors	30
2.2.4	Repurposing Drugs	32
2.3	Conclusions	33
3	Genome-Based Personalized Medicine in Liver Cancer	39
	<i>Jae-Jun Shim and Ju-Seog Lee</i>	
3.1	Introduction	39
3.1.1	Epidemiology of Liver Cancer	39
3.1.2	Clinical Characteristics of Liver Cancer	40
3.2	Why Personalized Medicine is Important in Patients with Liver Cancer?	41
3.3	Methods and Results of Genomic Profiling of Liver Cancer	42
3.3.1	Comparative Genomic Hybridization (CGH)	42
3.3.2	Microarray-Based Technology	43
3.3.3	Next-Generation Sequencing	44
3.3.4	Integromics: Integration of Multiple -omic Data	45
3.4	Conclusion	47
4	Applications of Circulating DNA Analysis in Personalized Medicine	53
	<i>Dana W. Y. Tsui and Muhammed Murtaza</i>	
4.1	Biological Characteristics of Circulating DNA	53
4.1.1	History	53
4.1.2	Biological Characteristics	54
4.2	Molecular Methods for Circulating DNA Analysis	55
4.3	Circulating Tumor-Specific DNA in Cancer Patients	58

4.3.1	Monitoring of Tumor Burden and Disease Response	58
4.3.2	Molecular Stratification for Targeted Therapies	59
4.3.3	Analysis of Clonal Evolution and Therapeutic Resistance	60
4.4	Circulating DNA for Noninvasive Prenatal Diagnostics	60
4.4.1	Noninvasive Diagnosis of Fetal Genetic Diseases	61
4.4.2	Noninvasive Prenatal Diagnosis of Down-Syndrome	61
4.4.3	Noninvasive Sequencing of the Fetal Genome	62
4.4.4	Clinical Implementation of Prenatal Diagnosis	63
4.5	Circulating DNA in Transplant Recipients	63
4.6	Pre-analytical Considerations	63
4.7	Conclusion	65
5	Circulating Tumor Cells and Personalized Medicine	77
	<i>Jin Sun Lee, Mark Jesus M. Magbanua, Marc R. Jabon, and John W. Park</i>	
5.1	Metastasis and Circulating Tumor Cells	77
5.1.1	The Metastatic Process	78
5.1.2	Circulating Tumor Cells	79
5.2	Enrichment and Detection of CTCs	79
5.2.1	Enrichment	80
5.2.2	Detection	82
	5.2.2.1 Immuno-cytomorphological approach: Immunocytochemistry (ICC)	82
	5.2.2.2 Molecular approach: Real-time reverse transcription polymerase chain reaction (RT-PCR)	84
5.3	Clinical Implications of CTC Detection and Enumeration	84
5.3.1	Breast Cancer	85
5.3.2	Prostate Cancer	86
5.3.3	Colorectal Cancer	87
5.3.4	Lung Cancer	88
5.4	Molecular Characterization of CTC and Personalized Medicine	89

5.4.1	Tumor Biomarkers in CTCs	89
5.4.2	Molecular Analysis of CTCs	90
5.4.3	Clinical Trials for Personalized Medicine	90
5.5	Summary	92
6	Mouse Models in Personalized Cancer Medicine	103
	<i>M. E. Beaulieu, T. Jauset, D. Massó-Vallés, L. Soucek, and J. R. Whitfield</i>	
6.1	Transgenic Mouse Models: From Understanding the Molecular Basis of Tumorigenesis to the Refinement of Drug Design Targeting Specific Mutated/Altered Proteins	104
6.1.1	Prenatal GEMMs	105
6.1.1.1	Tissue-specific promoters and CRE recombinase technology	105
6.1.2	Postnatal GEMMs	107
6.1.2.1	Irreversible models: Inducible CRE recombination	107
6.1.2.2	Switchable models: The tetracycline inducible system	108
6.1.2.3	The estrogen-receptor system	110
6.1.3	GEMMs: Benefits and Drawbacks	111
6.2	Patient-Derived Xenograft (PDX): Tumor Heterogeneity and the Exploration of Avatars as Predictors of Treatment Outcome	112
6.2.1	Starting Material	113
6.2.2	Mode of Implantation	115
6.2.3	Recipient Mouse Strains	116
6.2.4	PDXs in Personalized Medicine	117
6.2.5	PDXs: Limitations and Value	121
6.3	Humanized Mouse Models: Bringing the Major Players Back into the Biological Game	122
6.3.1	The Need for Better Models	122
6.3.2	"Humanizing" the Mouse Models	123
6.3.3	Transplantation of Hematopoietic Stem Cells	124
6.3.4	Transplantation of Peripheral Blood Mononuclear Cells	125
6.3.5	Local "Humanization"	125

6.3.6	Overcoming Limitations of the Model	126
6.3.7	Success Stories	126
6.3.8	Humanized Mouse Models: Future Perspectives	128
6.4	Discussion and Perspectives	128
7	Tumor Microenvironment, Therapeutic Resistance, and Personalized Medicine	145
	<i>Yu Sun</i>	
7.1	TME Orchestrates Disease Progression and Dominates Therapeutic Response	146
7.1.1	Cancer-Associated Fibroblasts	147
7.1.2	Vasculature System	148
7.1.3	Extracellular Matrix	148
7.1.4	Immune Cells	149
7.1.5	TME-Derived Exosomes	151
7.2	Treatment-Activated TME Confers Acquired Resistance and Creates Barriers to a Clinical Cure	154
7.2.1	Damage Responses of the TME Offset Therapy-Enforced Tumor Regression	154
7.2.2	Modified Differentiation and Immune Responses in the TME Decrease Therapeutic Outcomes	157
7.3	Overcoming Challenges of Personalized Cancer Therapy Requires Translation of Biological Insights into the Clinic	158
7.3.1	Implications of Personalized Cancer Therapy in an Era of Precision Medicine	158
7.3.2	Significance of Preclinical Studies in Promoting PCT Advancement	163
7.4	Concluding Remarks and Future Outlooks	165
8	Personalized Immune Therapy	175
	<i>Joost Hegmans, Lysanne Lievense, and Joachim Aerts</i>	
8.1	Immunotherapy	176
8.2	Immune Cell Involvement during Carcinogenesis	177
8.3	Context-Specific Nature of Immune Cells within Tumors	177

8.4	Types of Immunotherapeutic Approaches	179
8.4.1	Biological Response Modifiers	180
8.4.2	Monoclonal Antibodies	180
8.4.3	Tumor Vaccines	181
8.4.4	Cellular Immunotherapy	181
8.4.4.1	Dendritic cell-based immunotherapy	182
8.4.4.2	Adoptive genetically modified and/or expanded T-cell therapy	182
8.4.4.3	Adoptive natural killer (T) cells' transfer	183
8.5	The Future of Personalized Medicine	183
9	Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Malignancies	189
	<i>G. E. Bates, P. Kim, C. M. DeRosa, L. Petrukhin, Y. Bressler, and R. N. Taub</i>	
9.1	What Is Hyperthermic Intraperitoneal Chemotherapy (HIPEC)?	189
9.2	The Role of Heat as a Cytotoxic Agent	191
9.3	The Role of Heat Shock Proteins in HIPEC Treatment	192
9.4	Chemotherapeutic Agents Used for HIPEC	193
9.4.1	Cisplatin: [cis-diamminedichloroplatinum(II) (CDDP)] (Platinol and Platinol-AQ)	193
9.4.2	Doxorubicin: (7S,9S)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione)	194
9.4.3	Carboplatin: (cis-diammine-1,1-cyclobutane dicarboxylate platinum II, CBDCA, JM8)	195
9.4.4	Melphalan: 4-[bis(chloroethyl)amino]phenylalanine]	195
9.5	Quality-of-Life Impact of HIPEC Treatment	196
9.6	The Future of HIPEC: The Need for Personalization	197

10	Personalized Medicine in Hereditary Cancer Syndromes	199
	<i>Rishi Agarwal and Vivek Subbiah</i>	
10.1	Introduction	199
10.2	Neurofibromatosis Type 1	201
10.3	Neurofibromatosis Type 2	203
10.4	Gorlin Syndrome	204
10.5	Hereditary Breast and Ovarian Cancer Syndrome	205
10.6	Lynch Syndrome	208
10.7	Familial Adenomatous Polyposis	208
10.8	Fanconi Anemia	210
10.9	Inherited Medullary Thyroid Cancer	211
10.10	Tuberous Sclerosis Complex (TSC)	212
10.11	RASopathies	213
10.12	Von Hippel–Lindau Disease	214
	10.12.1 Tyrosine Kinase Inhibitors (TKIs)	215
	10.12.2 mTOR Inhibitors	216
	10.12.3 Anti-VEGF Receptor Antibodies	216
	10.12.4 Other Agents Including Histone Deacetylases (HDAC) Inhibitor	217
10.13	Cowden Syndrome	217
10.14	Proteus and Proteus-Like Syndrome	218
10.15	Li–Fraumeni Syndrome	218
10.16	Conclusions	219
11	Pathology in the Era of Personalized Medicine	227
	<i>Hye Seung Lee</i>	
11.1	Why Is the Role of Pathologists in Personalized Medicine Important?	228
11.2	Practical Guidance for Molecular Pathology	229
	11.2.1 Preanalytic	229
	11.2.2 Analytic	230
	11.2.3 Quality Assurance	232
	11.2.4 Postanalytic	233
11.3	Next-Generation Sequencing and the Pathologist	234
11.4	Conclusions	235

12 MicroRNAs in Human Cancers	239
<i>Tae Jin Lee and Carlo M. Croce</i>	
12.1 Introduction	239
12.2 Biogenesis and Working Mechanism of MicroRNA	242
12.3 MicroRNAs as Tumor Suppressors	244
12.4 MiRNAs as Oncogenes	245
12.5 MiRNAs and Epigenetics	247
12.6 MiRNA Signatures in Human Cancers	248
12.7 Biomarker MiRNAs in Human Cancers	249
12.8 Circulating MiRNAs as Biomarkers of Human Cancers	251
12.9 Single Polymorphism (SNP) in MiRNAs	252
12.10 MiRNA and Cancer Stem Cells	253
12.11 Perspectives	253
13 Pharmacogenomics of Tamoxifen	265
<i>Hitoshi Zembutsu</i>	
13.1 What Is Tamoxifen?	266
13.2 Why Is Pharmacogenomics of Tamoxifen Important?	266
13.2.1 Metabolic Pathway of Tamoxifen	267
13.2.2 <i>CYP2D6</i> Genotype and Pharmacokinetics of Tamoxifen	269
13.2.3 <i>CYP2D6</i> Genotype and Tamoxifen Efficacy	269
13.3 The Controversy in Tamoxifen- <i>CYP2D6</i> Study	270
13.4 Future Direction of Tamoxifen Pharmacogenomics	271
13.4.1 Pharmacogenomics for Irinotecan: <i>UGT1A1</i>	271
13.4.2 Pharmacogenetic Test of <i>CYP2C9</i> and <i>VKORC1</i> Genotypes for Warfarin Treatment	272
Index	279